DNA Vaccine Delivery - Development of the ideal DNA vaccine requires the optimization of delivery strategies and plasmid vectors. - BioPharm International

ADVERTISEMENT

DNA Vaccine Delivery
Development of the ideal DNA vaccine requires the optimization of delivery strategies and plasmid vectors.


BioPharm International Supplements
Volume 24, Issue 10, pp. s12-s18

REFERENCES

1. M.A. Lui, Immunol. Rev. 239, 62–84 (2010).

2. "West Nile-Innovator DNA", Fort Dodge Animal Health. E0257D 15M AP (Nov. 2008).

3. N.C. Simard, "The Road to Licensure of a DNA Vaccine for Atlantic Salmon", http://www.bion.no/filarkiv/2010/07/vaccine_simard.pdf, accessed Aug. 2011.

4. S. Vasan et al., PLoS One 6 (5), e19252 (2011).

5. K.E. Broderick et al., Hum. Vaccines 7, 22–28 (2011).

6. T. Kardos. "Contactless Magnetic Electroporation" presented at the DNA Vaccines Conference (San Diego, CA, 2011).

7. M.R. Prausnitz et al., Microbiol. Immunol. 333, 369–393 (2009).

8. J.W. Hooper et al., Vaccine 25, 1814–1823 (2007).

9. A.K. Roos et al., Mol. Ther. 13 (2), 320–327 (2006).

10. L.A. Hirao et al., J. Infect. Dis. 203 (1), 95–102 (2011).

11. D.J. Laddy et al., J. Virol. 83 (9), 4624–4630 (2009).

12. P.T. Loudon et al., PLoS One 5 (6), PLoS ONE doi:10.1371/journal.pone.0011021, Jun. 8, 2010.

13. M.A. Kutzler and D.B. Weiner, Nature Rev. Genetics 9, 776–788 (2008).

14. M. Shata et al., Mol. Med. Today 6, 66–71 (2000).

15. P.M. Smooker et al., Biotechnol Annual Rev. 10, 189–236 (2004).

16. G. Dietrich, A. Collioud, and S.A. Rothen. Biopharm Intl. 21 (10) s6–s14 (2008).

17. A. Edwards and N.K.H. Slater, Vaccine 27, 3897–3903 (2009).

18. FDA, Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information. (Rockville, MD, Sept. 2010).

19. J.M. Huang et al., Vaccine 28, 7523–7528 (2010).

20. J. Bergin, "DNA Vaccines: Technologies and Global Markets," BCC Research (2009)


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here